1 – 7 of 7
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic
(
- Contribution to journal › Article
- 2019
-
Mark
Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management : A prespecified subgroup analysis from VALIDATE-SWEDEHEART
(
- Contribution to journal › Article
-
Mark
Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction
(
- Contribution to journal › Article
- 2017
-
Mark
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction
(
- Contribution to journal › Article
-
Mark
Bivalirudin versus heparin monotherapy in myocardial infarction
(
- Contribution to journal › Article
- 2015
-
Mark
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
(
- Contribution to journal › Article
- 2012
-
Mark
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
(
- Contribution to journal › Article